WebNov 4, 2024 · Genmab's DuoBody-CD3 technology is designed to direct cytotoxic T cells selectively to tumors to elicit an immune response towards malignant cells. ... Forward-Looking Statements Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of … WebJun 22, 2024 · T: +1 609 524 0065; E: [email protected]. For Investor Relations: Andrew Carlsen, Vice President, Head of Investor Relations. T: +45 3377 9558; E: …
BioNTech and Genmab Expand Global Strategic Collaboration to …
WebJun 6, 2024 · To develop and deliver novel therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. Genmab’s … WebAug 5, 2024 · Genmab A/S Tel: +45 7020 2728 Media Release no.12 Kalvebod Brygge 43 www.genmab.com Page 1/3 1560 Copenhagen V, Denmark CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122 ... This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. eric sonye
Genmab and Synaffix Enter into License Agreement for ADC Technology
WebApr 6, 2024 · Company Announcement. COPENHAGEN, Denmark; April 6, 2024 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) made by managerial employees … WebCompany Announcement COPENHAGEN, Denmark; February 28, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 24,359 shares as a consequence of … ericson xg2-14-2s